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Introduction 
According to sentinel lymph node (SLN) hypothesis, tumor 
cells migrate in an orderly manner from a primary tumour, 
metastasizing to one or a few LNs before involving others. 
Therefore, SLN is defined as the first LN that receive 
lymphatic drainage from the primary tumour, if the tumour 
has spread. The advent of percutaneous lymphoscintigraphy 
allowed Robinson et al. identify lymphatic drainage patterns 
of melanomas and the development of SLNB technique 
through intraoperative lymphatic mapping (1). 
Locoregional spread of breast cancer (BC) occurs mainly 
through the lymphatic system. SLN status accurately 
predicts the status of the other LNs and is important to 
establish staging and prognostic outcomes of BC.
SLNB, as ideal nodal staging method for BC, was 
introduced by Krag et al. and Giuliano et al. in 1993 and 
1994 (2,3). Krag et al. described and developed the gamma 
probe localization of SLN with RI; Giuliano et al. described 
the SNB using BD alone as a procedure technically feasible, 
safe, and highly accurate to stage regional LNs in BC (4). 
SNB has since become the new standard of care for axillary 
staging in clinically and radiologically node-negative BC (5). 
Clinical trials demonstrated that in these kinds of patients 
a properly performed SLNB is equivalent to axillary 
lymph node dissection (ALND) for staging of axilla (6-8), 
identifying patients who need further axillary clearance, 
while sparing others a potentially morbid ALND (9).
This paper is a comprehensive review of the currently 
used techniques for SLNB with a specific focus on the new 
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innovative ones. 
Current standard of care for SLNB—blue dye 
and/or technetium labelled nanocolloid
The traditional SLNB techniques proposed by Giuliano 
et al. (4) and Krag et al. (3) have been developed both as 
single technique and as dual complementary procedure: the 
choice is determined by surgeon and institutional preference. 
Giuliano et al. reported a 93% SLN identification rate 
using BD alone, while Krag et al. reported a 82% SLN 
identification rate using only RI and gamma probe.
James et al. (10) accurately described best practices for both 
of these tracers besides to the main problems linked to them. 
Three types of BD have been described: isosulfan 
blue, methylene blue (MB) and patent blue. Each surgeon 
should look for the method that works best for his or her 
practice, even though isosulfan and patent blue seem to 
cause a higher rate of adverse reactions (11). Indeed one 
of the major problem of BD is a possible adverse reaction 
up to an anaphylaxis. In case of isosulfan blue it has been 
reported in 0.7% to 1.1% of cases (12,13). MB has a 
reduced risk of anaphylaxis but showed side effects as well 
(14,15): skin necrosis and induration with associated pain, 
up to pulmonary edema and serotonin syndrome in patients 
who take serotonergic medications (16). To reduce the 
potential side effects, the BD are routinely diluted with 
normal saline (practices vary from 1:1 to 1:7 dilution) (17). 
Patient should be screened for known allergies and routine 
prophylaxis is not suggested as a standard but addressed 
to high risk cases. The injection site has been widely 
discussed: peripherically to the tumor, in correspondence 
of the palpable edge of the biopsy cavity, in the periareolar 
site or into the subareolar plexus. Chagpar et al. showed 
that subareolar and periareolar injection produced higher 
SLN identification rates than peritumoral injection (18). 
Even though some authors claim that MB diffuses more 
rapidly in peripheral tissues, staining a larger portion of 
the breast with the BD and, to a certain extent, hampering 
the procedure (19,20), other authors have reported similar 
accuracy and SLN detection rates (DRs) with MB and with 
patent blue (21). MB is also much more readily available 
in different hospitals and less expensive than the others 
(the cost of MB may represent as little as 3% of the cost 
of patent blue or isosulfan blue) (22). Another advantage 
of MB is the possibility to be used during pregnancy (23). 
In a recent prospective randomized trial MB performed as 
well as patent blue in identifying SLN in BC (24). MB has 
so become a standard widely used in USA. Krikanova et al. 
reported a 94.6% SLN identification rate using BD alone 
making this technique very attractive in high volume units 
without nuclear medicine facilities or where these facilities 
are available but when added cost and logistical issues 
regarding transport of tracer are problematic (25). 
The most used RI tracer is the Technetium 99m (99mTc), 
99mTc-sulfur colloid in USA and 99m Tc-nanocolloid human 
serum albumin in Europe. It can be injected before surgery 
around the tumor, intradermally or into the subareolar 
plexus. Intradermal injection of radiocolloid appears to be 
superior to subdermal injection (26-28). Recently Berrocal 
et al. described the intraoperative injection of 99mTc in 
a large series of patients: they reported this method as 
convenient, effective, safe, and comfortable for the patient 
with a SLN DR that was essentially 100% (29). A handheld 
scintillation counter (gamma probe) is used to guide the 
surgeon to the labeled LNs. LNs are removed following the 
“10% rule” (all LNs with counts >10% of ex vivo count of 
the most radioactive node should be removed) (30). 
The use of RI creates logistical challenges for hospitals, 
including the handling and disposal of isotopes, training of 
staff and legislative requirements. The 6h half-life of the 
isotope restricts scheduling of surgery because the injection 
is done by the nuclear medicine department. Additionally, 
patients might express reluctance to being exposed to 
radiation and not all of them (mainly the frail patients) have 
the possibility to reach an hospital with access to RIs (31). 
These factors have limited the uptake of SLNB worldwide 
for hospitals without access to RIs (29). Growing interest is 
arising in development of new and possibly more effective 
radio-tracers. New 99mTc-tilmanocept (99mTc-TM) showed 
similar SLN uptake to 99mTc–sulfur colloid but with a rapid 
injection site clearance, high SLN extraction, low distal 
node accumulation and no significant pain associated with 
injection (32). In comparison to 99m Tc-nanocolloid human 
serum albumin used in Europe showed higher localization 
rate and degree of  local ization.  99mTc-TM has no 
contraindications, and no serious adverse or hypersensitivity 
reactions were reported (33). Another interesting 
radiotracer has been developed by Li et al.: 99mTc-rituximab. 
It contains 99mTc-labeled monoclonal antibody targeting 
CD20 abundantly expressed on the surface of B cells in 
LNs. The advantage is its uniform molecular weight and 
molecular size so it will not escape easily from SLNs to 
the second-echelon LNs achieving a clear SLN imaging in 
patients and high success rate of lymphoscintigraphy. The 
sensitivity, specificity, and accuracy of SLNB was 97.40%, 
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100% and 98%, respectively; the FN rate was 2.60%, which 
is better than that of other studies (FN rate ranging from 6% 
to 10%); moreover, its feasibility, safety, and effectiveness 
have been confirmed by clinical SLNB application with 
large samples (34). Recently İlem-Özdemir et al. prepared a 
new RI for SLN mapping which chemically combined a RI 
and a BD, the 99mTc-isosulfan blue, to be injected as a single 
dose. They examined its effectiveness in mapping LNs in 
rats with promising results (35).
Although excellent results are reported in single-
institution series using either radioactive colloid or BD 
(4,36,37) combined use of both tracers appears to be 
complementary, minimizing the FN rate in most (17,18,38) 
but not all, studies (39). Motomura et al. demonstrated that 
the combination of BD and RI is superior to dye alone for 
SLNB in terms of identification rate (95% vs. 84%) and 
sensitivity (100% for the combination) (40). 
Therefore, the actual gold standard for SLNB is the dual 
tracer technique which assures higher SLN identification 
rates and lower FN rates (41,42). It is particularly indicated 
for surgeons with limited experience and in cases where 
misidentification and FN rates are known to be higher 
(neoadjuvant therapy, prior breast/axillary surgery, obese 
patients and when the use of BD or radioactive colloid 
alone fails to produce a signal in the axilla) (43,44). In the 
dual technique the BD helps with localization post-incision, 
and LNs that are radioactive, blue, or both are recognised 
as SLNs (45). 
Lymphoscintigraphy is not suggested to be used as 
routine but only in the cases at higher risk of failing the SLN 
identification (i.e., previous breast or axillary surgery) (46). 
In a meta-analysis of more than 8,000 patients from a 
systematic review of 69 trials about SLNB, the identification 
rate of these nodes was 96%, with a FN rate of 7.3% (range 
0% to 29%) (47). The identification rate with the dual 
technique was 97% in the AMAROS trial among 1953 
patients with an operable invasive T1-2 BC without clinical 
suspect regional LNs (48), and 99.1% in patients in the 
SENTINA trial with advanced disease undergoing SLNB 
before commencing neoadjuvant chemotherapy (49). In the 
ALMANAC trial, the dual technique identified SLNs in 
96% of patients, but only 85.6% with RI or BD alone (50). 
In the NSABP B-32 trial, the SLNs were identified in 
more than 97% of patients (51). Most of the SLNs were 
both hot and blue (65%), while 24% were hot only, 5% 
were blue only, and 3.9% were neither hot nor blue, but 
palpably abnormal (this can be explained since gross tumor 
involvement interferes with the uptake of both radiocolloid 
and BD, and lymph flow is diverted to a node other than the 
true SLN. That’s why all axillary palpably abnormal LNs 
should always be removed). Removal of two SLNs rather 
than one almost halved the FN rate: in fact the FN rate in 
this study was 9.8% and was related to the number of SLNs 
removed: it was 17.7% when only one node was removed, 
10% for two nodes, 6.9% for three nodes, and 5.5% for 
four nodes. This trial also showed no significant difference 
in overall and disease-free survival between those patients 
undergoing SLNB followed by automatic ALND and those 
undergoing SLNB followed by ALND only if the SLNs 
were identified as positive (6). In a systematic review by 
the American Society of Clinical Oncology, the use of both 
BD and RI was associated with an almost significant trend 
toward fewer FN results (7% vs. 9.9%) (42). 
James et al. (10) particularly stressed the importance of 
surgeon experience in the accuracy of SLN identification. 
This was also confirmed by a recent multicenter trial (52). 
After five training cases, the success rates for individual 
surgeons identifying a SLN ranged from 79% to 98%. 
Furthermore, Cox et al. showed that surgeons who 
performed more than six SLNBs per month had lower 
failure rates (53). Proper surgical technique in SLNB 
influences outcomes and minimizes the risk of understaging 
and undertreating patients (10).
The constraints of the existing combined SLNB 
technique have led to the development of alternative 
methods which will be the object of the following 
description and review.
New techniques and future perspectives in SLNB
In recent years new techniques for SLNB have been 
successfully developed. They use innovative tracers such 
as indocyanine green (ICG), superparamagnetic iron oxide 
(SPIO), and microbubbles. Whilst each technique has its 
own advantages/disadvantages (Figure 1), they have shown 
promising but variable results between studies, small patient 
numbers and short patient follow-up (45). So they have to be 
considered still investigational until there is a final evidence 
that they are accurate in SLNB with a low FN rate. 
Indocyanine green (ICG)
ICG is a FDA approved, low molecular weight organic 
molecule, which fluoresces in the near infrared (NIR) part 
of the spectrum where tissue absorption of light is minimal 
and has a well-established safety profile. ICG was initially 
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advanced as a visible dye marker in the detection of SLNs, 
and as such had comparable success to conventional dyes 
(74% DR in BC) (54). With improvements to image 
capturing technology (such as sensitive infrared cameras, 
the photodynamic eye—PDE or the newer Fluorescence 
Assisted Resection and Exploration—FLARE imaging 
system), the use of ICG as a NIR fluorophore improved 
the DR to approximately 95% (55). The fluorescence 
signal is captured by the PDE using a light-emitting diode 
producing light at a wavelength of 760 nm in its active 
state. The detector is a charge-coupled device camera that 
filters out wavelengths below 820 nm. This NIR fluorescence 
imaging system visualizes subcutaneous lymphatic flow in real 
time, as a real time lymphography, and navigates the surgeon 
to enable an orderly and sequential dissection of SLN. 
ICG is injected directly into the breast. The injection 
site is hugely variable according to the different reported 
experiences. The majority of studies use periareolar or 
Figure 1 Advantages/disadvantages of new SLNB techniques in BC. ICG, Indocyanine green; SPIO, superparamagnetic iron oxide; CEUS, 
contrast enhanced ultrasound; SLN, sentinel lymph node; US, ultrasound; SLNB, sentinel lymph node biopsy; BC, breast cancer.
Advanages/Disadvantages of new techniques
ICG
Advantages
	real time visualization 
	cheap
	quick
	no nucealr medicine department 
needed
	no severe allergic reactions reported 
Disadvantages
	low molecular weight
	ICG leaking out after SLN is recised
	difficult to be detected at a depth of 
more than 1 cm 
	can not be used in patients with 
iodine allergy
SPIO
Advantages
	short preparation time 
	comfortable timeframe
	appropriate molecular weight
	several years shelf-life 
	fast learning curve 
	brown colour helps during axillary 
dissection
	do not require any special storage 
	no nucealr medicine department 
needed
	no severe allergic reactions  
reported 
Disadvantages
	large diameter of the magnetomer 
	regular re-balancing of the probe 
during usage
	possible interference of the 
surgical instrumentation with the 
ferromagnetic signalling 
	magnetometer does not reach the 
same depth as a gamma probe 
	intra-mammary persistence which 
can create void MRI artefacts 
	can not be used in patients with 
hypersensitivity to iron or dextran 
compounds and those with 
pacemakers or metal implants 
CEUS with microbubbles
Advantages
	real time visualization 
	cheap
	requires only a US apparatus and a 
contrast agent
	no nucealr medicine department 
needed
	no severe allergic reactions reported 
Disadvantages
	long learning curve
	not so quick as the others
	CEUS is operator dependent
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retroareolar subdermal injection, even though ultrasound-
guided injection of ICG near to and surrounding 
ultrasound-identified SLN has been reported (45). 
Samorani et al. described a protocol of subareolar injection 
for multicentric BC and intradermal injection for unicentric 
BC (56). The injected quantity may depend on the surgeon 
preferences, the breast volume and the BMI of the patient. A 
recent meta-analysis showed as ICG injection with reduced 
concentration (<5 mg/mL) and larger volume (≥2 mL) may 
increase sensitivity and DR (57). A quick breast massage 
should follow the injection. The time between the injection 
and the incision varies but it should happen by 10 min. The 
SLNs are then localized using a fluorescent imaging system 
(56-58): the tracer progress is followed through the lymphatic 
ducts to the SLN using an excitation illumination system in 
combination with a high sensitivity camera, which detects 
the emitted fluorescence. The axillary skin incision should 
be made only when the tracer has visibly reached the axilla, 
not before, otherwise, by interrupting the vessels too soon, 
the detection of SLNs becomes much more difficult (56). 
ICG fluorescence is scattered by superficial tissues and is 
difficult to be detected at a depth of more than 1 cm. Thus 
caution is required when searching for SLNs at lower 
depths particularly in obese patients.
A major advantage of ICG is that it enables real time 
visualization of lymph flows from the breast to the axilla. 
Thus, SLNs can be identified and resected more rapidly 
and easily, especially in cases with multiple lymph drainage 
pathways, where ICG can detect multiple SLNs. ICG is 
reported to be much cheaper compared with a radiotracer. 
The fluorescence imaging device is also cheaper than a 
gamma probe. Five milligrams of ICG costs about $1.50, 
while a radiotracer is about $200 in Japan (59). Therefore, 
as a result of the lower cost, patients in developing 
countries may also benefit from ICG tracer. Moreover, 
the involvement of a nuclear medicine department is not 
necessary and there is no exposition to radiations. On 
the other hand, it has been observed a higher number 
of SLNs identified with ICG, probability due to the low 
molecular weight which translate into rapid migration in 
the lymphatics spreading beyond the SLN to secondary 
draining LNs (55). In their review Ahmed et al. (45) 
reported a mean number of nodes excised between 3 and 
5.4 for ICG and between 1 and 2.4 for BD. ICG probably 
travels to higher echelon nodes than BD does, resulting in 
unnecessarily excessive dissection and removal of nodes. 
Furthermore, when the first SLN is resected, lymph 
vessels are cut and ICG leaks out. The leaked ICG spreads 
to the surgical field, making it difficult to detect another 
fluorescent node. This problem can be solved by reducing 
the amount of ICG. Lastly ICG cannot be used in patients 
with iodine allergy, because it contains iodine.
Since ICG fluorescence is visualized by collecting 
NIR rays in dimmed light conditions, recently Toh et al. 
developed a new promising ICG imaging system called 
HperEye, which allows the transcutaneous visualization 
of lymphatic vessels under normal light conditions, thus 
facilitating the identification and detection of SLNs without 
affecting the surgical procedure, together with a high 
sensitivity and specificity (60).
Ahmed et al. found that ICG was significantly better 
than BD in terms of improved SLN identification, while 
there was no statistically significant difference between 
ICG and RI although almost all showed SLN identification 
to be higher with ICG. No difference was noticed also 
between ICG and the dual technique. They reported a 
SLN identification rate between 93.1% and 100% (in 11/15 
studies) of patients (45).
Increasing clinical results for the ICG method support a 
higher SLN DR (99–100%) compared with the use of BD 
(61,62). Moreover, several clinical trials demonstrated that 
ICG method is safe and achieves a high SLN DR that is 
comparable or superior to the RI method (56,63-65). Sugie 
et al. reported a similar overall DR of SLNs between ICG 
and RI with a significant improvement achieved by the 
combination of methods compared with RI alone (66). Tong 
et al. showed that a combined ICG and BD tracer technique 
was superior to the use of BD alone for identifying SLNs 
with higher sensitivity, and for predicting axillary LN status 
in patients with BC; in addition, the combined technique 
had reduced FN results (67). Similar results were reported 
by Hirano et al. in a large series of patients (59). Samorani 
et al. reported their experience in the use of ICG only for 
SLNB and they demonstrated that there are no advantages 
in the association of ICG with BD, as the use of ICG only, 
once the technique is mastered, allows, always and in every 
case, the removal of the SLN with a 100% DR (68). On 
the other hand, Ji et al. affirmed that the efficiency and 
sensitivity of SLNB can be improved by combining ICG 
with BD since the use of blue tracer significantly decreased 
the average time to detect each SLN, and it increased the 
number of SLNs identified (69).
To confirm the importance of this upcoming technique 
a recent meta-analysis by Zhang et al. reported that ICG 
guided SLNB had a 98% DR; the pooled sensitivity (0.92) 
and specificity (1) were relatively high and the FN rate was 
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relatively low (8%) going down to 4% when when ICG 
was combined with BD; in the presence of metastases, the 
diagnostic performance of this method was good, with 
relatively high sensitivity and very high specificity (70). 
The last published meta-analysis on this topic of 
12 non-randomized comparative studies, reported that 
ICG was equal to or better than RI in localizing SLNs and 
tumor-positive SLNs. These results confirm that the ICG 
fluorescence method is a useful alternative to the standard 
RI method for SLNB (71). 
No severe adverse events directly related to the ICG dye 
have been reported. Recent improvements in this technique, 
combined with its good safety profile, made the use of 
ICG to find SLNs an attractive and promising alternative 
for SLNB in BC. However, a good standardisation of the 
technique between studies is low, which makes it difficult 
to reliably draw final conclusions. This shows how this 
technique is still in development with significant refinement 
necessary (45).
Superparamagnetic iron oxide (SPIO)
SPIO is a non-invasive magnetic tracer for SLNB detected 
by a handheld magnetometer. The SentiMAG multicentre 
trial (72) was the first trial that evaluated this new magnetic 
technique for SLNB against the standard one. When 
injected subcutaneously, SPIO moves into SLNs within 
minutes, and iron deposition is seen predominantly within 
sinuses and in macrophages. In the event of metastatic 
involvement of the node, SPIOs are seen to deposit within 
uninvolved areas of the node only (73). The nodes can 
be visualized on magnetic resonance imaging (MRI) and 
at operation are often colored brown or black (74). The 
SentiMAG trial group developed 2 CE marked devices: 
an injectable magnetic tracer (Sienna+) and a handheld 
magnetometer (SentiMag) that generates an alternating 
magnetic field which temporarily magnetizes the SPIO 
and senses the particles’ magnetic response. The particle 
diameter of Sienna+, including its organic coating, is 
60 nm. It is ideally suited for SLNB since this diameter 
enables the SLNs to selectively filter out the particles and 
is similar to the particle size of standard RI tracers. The 
diameter of the magnetometer is slightly larger (6 mm) 
than that of the gamma probe. The magnetic technique 
was well standardized. A 5 mL periareolar subcutaneous 
injection was administered, consisting of 2 mL of magnetic 
tracer (Sienna+) diluted with 3 mL of normal saline. This 
was injected intraoperatively (after induction of anesthesia) 
followed by a 5 min massage. The median Sienna+ 
migration time before surgery was 20 min. The surgeon 
used the handheld magnetometer for the SLN localization. 
All SLNs detected intraoperatively by using the handheld 
magnetometer or gamma probe or nodes that were blue 
or black, were excised. All metal retractors were removed 
from the surgical field while the magnetometer was used. 
Excision of nodes identified by magnetometer followed the 
same “10% rule” used for the gamma probe. Any palpable 
nodes were also removed. They reported no difference in 
identification rate (95% with the standard technique and 
94.4% with the magnetic technique) and no difference in the 
average number of LN removed (1.9 vs. 2.0 per patient) (72). 
Similar results were achieved by the Central-European 
SentiMag study (75) reporting similar DRs between the 
standard RI technique and the magnetic one (97.3% vs. 
98.0%), with a similar average number of removed SLNs 
per patient and a higher per patient malignancy DR for the 
SPIO tracer.
In agreement with the previous experiences Rubio et al. 
showed no difference in DR between the standard RI 
technique and the magnetic one (95.7% vs. 98.3%) with a 
significant higher average number of SLN excised in the 
SPIO group (76).
The “IMAGINE” Spanish multicentre study reported 
similar DRs between RI technique and magnetic technique 
with the ex-vivo and intraoperative DRs at the node level 
slightly higher for the magnetic technique. The SPIO tracer 
also showed a higher per patient malignancy DR (77).
The French Sentimag Feasibility Trial evaluated the 
magnetic technique in comparison to the standard technique 
(RI with or without BD) (78). The DR was 97.2% for Sienna+ 
and 95.4% for the standard technique with more SLNs 
detected with Sienna+ (97.2% vs. 90.2%). Furthermore, the 
N+ status does not seem to be an obstacle for the magnetic 
method which shows a tendency to identify more involved 
SLNs, a trend already described by Thill et al. (75).
A meta-analysis of five clinical trials comparing Sienna+ 
to a standard technique confirmed that Sienna+ is non-
inferior with respect to SLN identification per patient, 
as well as per SLN. Importantly, non-inferiority was also 
shown with respect to the ability to accurately identify 
patients with malignant SLNs (79). 
In another recent meta-analysis of seven randomized 
trials by Zada et al., the SPIO technique was not inferior 
to the standard technique in identification rate (97.1% vs. 
96.8%), total LNs retrieved (1.9 vs. 1.8 nodes per patient), 
and FN rate (8.4% vs. 10.9%). There was a trend towards 
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a lower FN rate in favour of the magnetic technique, but 
this was not statistically significant. The total number of 
LNs retrieved was significantly higher with the magnetic 
technique. The mean discordance rate between the two 
techniques was 3.9% (range 1.7% to 6.9%) (80).
The SentiMag technique offers many advantages: 
surgeon can inject the magnetic tracer directly in the 
operation room, the preparation time is much shorter than 
for the RI, provides a very comfortable timeframe and the 
SPIO tracer is well retained in the “true” SLN. The shelf-
life of the magnetic tracer is several years and the learning 
curve seems to be very fast, especially if compared to the 
other techniques. The brown color does not seem to be 
sufficient to make identification alone but can help the 
surgeon during the axillary dissection. Sienna+ particles do 
not require any special storage and there are no radiation 
risks or any of the legislative controls associated with the 
handling of isotopes, neither for healthcare personnel 
nor for the patient. On the other hand, the diameter of 
the magnetometer is quite larger than the RI probe, even 
though a smaller one has been recently commercialized. 
Moreover, this technique requires a regular re-balancing 
of the probe during usage before each signal acquisition. 
Another technical limitation is a possible interference 
of the surgical instrumentation with the ferromagnetic 
signalling. To prevent it, the use of plastic surgical material 
is encouraged while the measurement with SentiMg is 
performed. Particular attention should be given to the 
intra-mammary persistence of Sienna+ which can create 
void artefacts and could hamper the interpretation of a 
postoperative breast MRI obscuring important clinical 
findings. Subareolar injections may have a higher risk of 
void artefacts than intratumoral or peritumoral injections 
of small magnetic tracer volumes, because the tumour area 
is excised (80). In a small study of ten MRI scans performed 
in six patients, void artifacts were noted at the subareolar 
injection site in all scans and all artifacts were greater than 
5 mm in greatest dimension. Based on current evidence, 
the magnetic technique should not be used in patients 
undergoing SLNB before primary chemotherapy (if MRI 
is used to assess response to treatment), those undergoing 
breast MRI surveillance (such as BRCA mutation carriers) 
or those with a mammographically occult tumour at 
diagnosis, in whom MRI may be required for further 
assessment or follow-up imaging (81). More research 
should clarify the patient cohort eligible for the magnetic 
technique and optimize the amount of magnetic tracer 
required. Another concern is that the magnetometer does 
not reach the same depth as a gamma probe, which can 
have consequences for the identification of deeper nodes, 
as demonstrated in the recently published MELAMAG 
Trial (82). Patients with hypersensitivity to iron or 
dextran compounds and those with pacemakers or metal 
implants were excluded from the clinical trials and would 
not be candidates for using Sienna+ for SLN mapping. 
A dermopigmentation is the most frequent complication 
reported at a rate up to 20% in correspondence of the 
injection site, which usually vanished over time (76,78). No 
severe allergic reactions were reported in any of the trials 
and meta-analysis reviewed.
All these encouraging results led to consider magnetic 
technique as feasible, but its performance should now be 
evaluated in a large randomized non-commercial controlled 
trial before clinical implementation (80).
SPIO enhanced MRI
Motomura et al. evaluated SPIO enhanced MRI for the 
detection of metastases in SLNs of patients with BC. A node 
was considered involved if the entire node or a focal area 
did not show low signal intensity on MRI. The sensitivity, 
specificity, and overall accuracy of MRI for the diagnosis of 
SLN metastases were 84%, 91%, and 89%, respectively (74). 
A more recent update by the same group introduced a 
SPIO enhanced MRI at 3T (83). They reported much 
better results: On a patient-by-patient basis, the sensitivity, 
specificity and accuracy of MRI for the diagnosis of SLN 
metastases were 100%, 96% and 97%. Authors concluded 
that SLNB may be avoided in patients with BC who have 
non-metastatic SLNs on SPIO-MRI.
The SentiMag multicentre trial imaging subprotocol 
evaluated the use of SPIO MRI for pre-operative 
localization of SLN and its potential for non-invasive 
identification of SLNs metastases (84). SPIO contrast 
agents are known to provide “negative contrast” on T2 
weighted MRI. SPIOs are injected interstitially, they are 
taken up by SLNs, and therefore SPIO MRI can be used as 
an alternative for pre-operative localization of SLNs which 
are visualized as a drop of signal intensity. LNs showing 
inhomogeneous SPIO uptake were classified as metastatic. 
SPIO-MRI successfully identified SLNs in 91% of patients. 
One patient had metastatic involvement of four LNs, 
and this was identified in one node on preoperative MRI. 
Two false positive cases were reported. The concordance 
between the number of nodes identified by imaging and 
during surgery was 55% for both the magnetic and the 
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combined technique. So it seems that SPIO MRI is a 
feasible technique for preoperative localization of SLNs 
and, in combination with intraoperative use of a handheld 
magnetometer, provides an entirely RI-free technique 
for SLNB. It gives the surgeon a detailed anatomical 
information on the location of the SLNs, which serves as a 
detailed surgical roadmap. Moreover, a noninvasive method 
that accurately diagnoses SLN metastases would prevent 
patients undergoing unnecessary SLNB. However further 
optimization of the technique and research with larger 
series of patients is needed.
Li et al. evaluated magnetic resonance lymphography 
with gadolinium (Gd-MRI) in SLN identification and 
metastasis detection in patients with BC (85). There was a 
significant correlation between the SLN numbers found by 
Gd-MRI and BD methods. Using BD as the gold standard, 
the sensitivity of Gd-MRL was 95.65% and the FN rate 
was 4.3% for axillary lymphatic metastasis detection. With 
heterogeneous enhancement and enhancement defect as the 
diagnostic criteria, Gd-MRL gave a sensitivity of 89.29% 
and specificity of 89.66% in discriminating malignant from 
benign SLNs.
Compared with SPIO-MRL, Gd-MRL is cheaper and 
more convenient. SPIO is a negative contrast and thus cannot 
image the lymph vessel. Compared with iopamidol-CT 
lymphography, Gd-MRL lacks radiation exposure, possibility 
of anaphylactic shock and nephrotoxic impairment (86). The 
good results achieved by this technique suggest a potential 
value in a future clinical practice.
Contrast enhanced ultrasound (CEUS) with 
microbubbles
This is an innovative technique where microbubble 
contrast agent, based on the use of dispersion with sulfur 
hexafluoride gas, is injected intradermally around the 
areola. Breast lymphatics are then visualized by CEUS and 
followed to identify and biopsy SLNs (87). 
Sever et al. tried to standardize a protocol (88). They 
performed a periareolar intradermal injection of 0.2–0.5 mL 
phospholipid-stabilised microbubbles containing sulphur 
hexafluoride gas with a mean diameter of 2.5 µm (Sonovue-
Bracco) reconstituted with 2 mL sterile saline. The breast 
was massaged for 10–30 s and lymphatic channels were 
visualised immediately on contrast pulse sequencing and 
followed into the axilla. The transit time from injection to 
arrival in the axillary nodes was 15–45 s. Areas of contrast 
accumulation were imaged with greyscale or live dual 
images to confirm the presence of an architecturally defined 
LN. The CEUS-identified SLNs were then localized with 
guidewires before undergoing SLNB with the standard 
dual technique. It resulted in SLN identification in 89% of 
patients (89). In a larger series by Cox et al. the technique 
failed to visualise or successfully biopsy 13.3% of patients, 
identifying positive SLN in 87.7%. There were 22 false-
negative results, which meant that sensitivity was 61% (low 
compared to the dual technique) and specificity 100% (87).
In the review by Ahmed et al. the standard dual technique 
was significantly better than CEUS in terms of SLN 
identification rate which anyway was between 87.7% and 
89% (45).
A recent meta-analysis of five studies reported the 
SLN identification rate ranging from 9.3% to 55.2%, the 
sensitivity from 61% to 89 %, the FN rate from 6.6% to 39% 
and the presence of micro/macrometastases from 1.9% to 
64.3% (90). 
Better results were achieved by Xie et al. who studied 
CEUS with Sonovue intradermal subareolar injection 
to localize SLN and the value of enhancing patterns 
in diagnosing SLN metastases (91). They showed no 
significant difference in SLN identification rate between 
CEUS and BD (97% vs. 96%). CEUS method detected 
less SLNs than BD while the positive rates of SLNs 
identified by CEUS was significantly higher than that by 
BD. Sensitivity of predicting SLNs metastases by CEUS 
enhancing pattern was 81.8%, the specificity was 86.2%, 
and the accuracy was 84.7%. They also described three 
patterns of enhancement of SLNs and the disomogeneous 
one was more common in involved SLNs.
In a preliminary clinical trial by Matsuzawa et al., 
CEUS was performed with a subareolar contrast injection 
to evaluate the SLN detection and intravenous contrast 
injection studied at color doppler to evaluate the presence of 
metastases in SLN, visualizing their microvascularities (92). 
The peripheral vascularization pattern was more frequently 
found in metastatic LNs. They used Sonazoid as contrast 
agent, a perflubutane microbubble that is stabilized using a 
phospholipid. Their results were very promising: sensitivity 
81.8%, specificity 95.2%, positive predictive value 90.0%, 
negative predictive value 90.9%, accuracy 90.6%.
Dellaportas et al. reported their experience with 
CEUS using totally intravenous contrast injection for 
a preoperative detection of malignant SLN (93). They 
showed a negative predictive value of 90% and positive 
predictive value of 75%. Overall sensitivity was 83.33% 
and specificity was 84.38%. Multivariate analysis showed 
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that the CEUS outcome was only correlated with the actual 
final histopathological report on the SLN. All the cases 
with 3 or more positive LNs were detected preoperatively 
with CEUS. They observed that involved nodes enhanced 
heterogeneously, with an early wash-in and wash-out 
enhancement.
Last meta-analysis published on this topic by Moody et al. 
evaluated whether CEUS-guided core biopsy of SLN could 
identify metastatic nodes preoperatively reducing the number 
of surgical SLNBs and whether CEUS SLN identification 
and localization is a viable alternative to standard lymphatic 
mapping using RI and BD (94). The SLN identification 
and localization rate for CEUS-guided skin marking was 
70–100% and for CEUS guided-wire localization was 
89–97%. Across the four studies that evaluated preoperative 
CEUS-guided SLNB, pooled sensitivity for identification of 
nodal metastases was 54% and pooled specificity 100%; the 
FNR ranged from 8% to 17%.
One advantage of this method is the real-time imaging 
for SLNs. It requires only a US apparatus and a contrast 
agent readily available on market so it is cheap and does not 
need radioactive materials. The patient is not exposed to 
radiation and the method is not invasive. CEUS guided core 
biopsy could potentially decrease the number of SLNBs 
and ALNDs in women with BC. CEUS has been proved to 
be accurate to identify and localize the SLNs preoperatively 
with SLN identification rates comparable to standard 
lymphatic mapping with RI and BD. So CEUS-guided SLN 
localizations may offer a viable alternative for developing 
countries that may not have access to nuclear medicine 
facilities. There are no iodine and proteins in sulfur 
hexafluoride microbubbles, which prevents patients from 
allergy. Indeed there have been reported no significant side 
effects or complications from the injection of microbubbles.
On the other hand, the learning curve for this technique 
seems to be quite long and the US still remains operator 
dependent. 
Even though it is a promising technique both for SLNs 
identification and for metastasizing SLNs detection, further 
studies are necessary to well standardize the method and 
improve the sensitivity and specificity. Randomized control 
trials with large series of patients are suggested in order to 
compare this technique with the current techniques used 
for SLN detection.
Conclusions
SLNB is still a stronghold in the management of early 
BC since the status of the axillary LNs remains one of the 
most important prognostic factors. Although the standard 
dual technique has reached a good level of standardization 
and accuracy it is burdened by several drawbacks. The use 
of RI creates logistical challenges for hospitals, legislative 
requirements, exposition to radiations both for the patient 
and for the healthcare staff. Moreover, the 6 h half-life 
of the isotope restricts scheduling of surgery because the 
injection is done by the nuclear medicine department. 
The development of new techniques in SLNB together 
with improvement in surgical strategies are clouding the 
traditional methods. Incoming experiences in endoscopic 
SLNB and ALND have been described, reporting low 
complication rates, better cosmetic results and similar 
efficacy to the traditional open axillary surgery (95). The 
new SLNB techniques seem to be safe, feasible and have 
shown very high improvements in accuracy, sensitivity and 
specificity in last years. It would be time to develop new 
comparative studies between the new techniques themselves 
to better clarify their value and efficacy. Anyway, all the last 
evidences show similar results or better than the traditional 
ones. Surgeon can be independent from the nuclear medicine 
department and can manage the operating independently. 
However, it should be well clarified how easy the availability 
of the new devices is and their relative cost. 
Since the new methods have now achieved a high 
qualitative standard and seem to be totally competitive 
with the traditional ones, randomized controlled trials are 
needed to assess their outcomes against the standard dual 
technique and be fully approved as new standard of care for 
SLNB. 
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